[1]张志萍.噻托溴铵结合福莫特罗粉吸入剂对慢阻肺患者肺功能指标的影响[J].医学信息,2021,34(23):102-104.[doi:10.3969/j.issn.1006-1959.2021.23.029]
　ZHANG Zhi-ping.Effect of Tiotropium Combined with Formoterol Powder Inhalation on Pulmonary Function Indexes in Patients with Chronic Obstructive Pulmonary Disease[J].Medical Information,2021,34(23):102-104.[doi:10.3969/j.issn.1006-1959.2021.23.029]
点击复制

噻托溴铵结合福莫特罗粉吸入剂对慢阻肺患者肺功能指标的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年23期
页码:
102-104
栏目:
论著
出版日期:
2021-12-01

文章信息/Info

Title:
Effect of Tiotropium Combined with Formoterol Powder Inhalation on Pulmonary Function Indexes in Patients with Chronic Obstructive Pulmonary Disease
文章编号:
1006-1959（2021）23-0102-03
作者:
张志萍
（抚州市临川区人民医院药剂科，江西 抚州 344000）
Author(s):
ZHANG Zhi-ping
(Department of Pharmacy,Linchuan District People’s Hospital,Fuzhou 344000,Jiangxi,China)
关键词:
噻托溴铵; 福莫特罗粉吸入剂; 慢阻肺; 肺功能
Keywords:
Tiotropium; Formoterol powder inhalation; Chronic obstructive pulmonary disease; Lung function
分类号:
R563.9
DOI:
10.3969/j.issn.1006-1959.2021.23.029
文献标志码:
A
摘要:
目的 观察噻托溴铵结合福莫特罗粉吸入剂对慢阻肺患者肺功能指标的影响。方法 选取2019年1月-2021年6月在我院诊治的64例慢阻肺患者，随机分为对照组和观察组，各32例。对照组采用福莫特罗粉吸入剂，观察组在对照组基础上给予噻托溴铵治疗，比较两组临床治疗总有效率、肺功能指标［呼气峰流速（PEF）、肺活量（FVC）、第1秒最大呼气量（FEV1）］、血气指标［动脉血氧分压（PaO2）、动脉血二氧化碳分压（PaCO2）］、运动耐量以及临床不良反应发生情况。结果 观察组治疗总有效率为93.75%，高于对照组的81.25%（P＜0.05）；治疗后，两组PEF、FVC、FEV1均大于治疗前，且观察组高于对照组（P＜0.05）；治疗后，两组PaO2均大于治疗前，PaCO2均低于治疗前，且观察组PaO2大于对照组，PaCO2小于对照组（P＜0.05）；治疗后，两组6 min步行距离均大于治疗前，且观察组大于对照组（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 噻托溴铵结合福莫特罗粉吸入剂治疗慢阻肺效果确切，可提高治疗疗效，显著改善肺功能指标，提升运动耐量，且不会增加临床不良反应，是一种治疗慢阻肺安全、有效的联合用药方法。
Abstract:
Objective To observe the effect of tiotropium combined with formoterol powder inhalation on pulmonary function in patients with chronic obstructive pulmonary disease.Methods A total of 64 patients with chronic obstructive pulmonary disease who were treated in our hospital from January 2019 to June 2021 were randomly divided into control group and observation group, 32 cases in each group. The control group was treated with formoterol powder inhalation, and the observation group was treated with tiotropium on the basis of the control group. The total effective rate of clinical treatment, pulmonary function indexes [peak expiratory flow (PEF), forced vital capacity (FVC), forced expiratory volume in one second (FEV1)], blood gas indexes [arterial partial pressure of oxygen (PaO2), arterial partial pressure of carbon dioxide (PaCO2)], exercise tolerance and clinical adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 93.75%, which was higher than 81.25% of the control group (P<0.05). After treatment, PEF, FVC and FEV1 in the two groups were higher than those before treatment, and those in the observation group were higher than the control group (P<0.05). After treatment, PaO2 in both groups was higher than that before treatment, PaCO2 was lower than that before treatment, PaO2 in the observation group was higher than that in the control group, PaCO2 was lower than that in the control group (P<0.05). After treatment, the 6 min walking distance of the two groups was greater than that before treatment, and that in the observation group was greater than the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion Tiotropium combined with formoterol powder inhalation is an effective and safe combination therapy for chronic obstructive pulmonary disease , which can improve the therapeutic effect, significantly improve lung function indexes, enhance exercise tolerance, and do not increase clinical adverse reactions. It is a safe and effective combination therapy for chronic obstructive pulmonary disease.

参考文献/References:

[1]张瓒,黄天霞,于虹,等.支气管哮喘、慢性阻塞性肺疾病和支气管哮喘-慢性阻塞性肺疾病重叠综合征的临床和肺功能特点对比[J].广西医学,2017,39(8):1262-1264.[2]冯旭,郭宏杰,丁峰.天晴速乐联合信必可吸入治疗哮喘-慢性阻塞性肺疾病重叠综合征对患者FeNO、血清总IgE、气道炎症因子及肺功能的影响[J].中国实用医刊,2020,47(3):97-101.[3]郭洁,武蕾,梁亚飞,等.小青龙汤加味联合信必可都保治疗对支气管哮喘患者炎症因子变化影响分析[J].中华中医药学刊,2018,36(1):207-210.[4]许迎辉,李响,韩玉英.噻托溴铵联合沙美特罗丙酸氟替卡松吸入治疗对慢性阻塞性肺疾病患者肺功能的影响[J].中国医药导报,2016,13(3):146-149.[5]中华医学会全科医学分会.慢性阻塞性肺疾病基层诊疗指南（2018年）[J].中华全科医师杂志,2018,17(11):856-870.[6]Stephanie M,Andrei M,Linda E,et al.Asthma and COPD overlap（ACO）is related to a high burden of sleep disturbance and respiratory symptoms: Results from the RHINE and Swedish GA2LEN surveys[J].PLoS One,2018,13(4):e0195055.[7]常秀群,肖志华.吸入激素噻托溴铵对哮喘-慢性阻塞性肺疾病重叠综合征的治疗效果分析[J].中国药物与临床,2019,19(8):1327-1328.[8]叶娟.信必可都保联合噻托溴铵治疗对COPD合并支气管哮喘患者肺功能、免疫功能及气道阻力的影响[J].标记免疫分析与临床,2019,26(2):264-268,289.[9]刘斌,冉献贵,邢青峰,等.噻托溴铵联合信必可都保治疗对慢阻肺患者肺功能和运动耐量及不良反应的影响[J].河北医学,2019,25(7):1108-1112.[10]李研,佟飞,米香.布地奈德福莫特罗粉吸入剂联合噻托溴铵粉吸入剂治疗ACOS的疗效及其对患者血清hs-CRP、EOS的影响[J].海南医学,2017,28(18):2997-3000.[11]张艳,李玲.信必可都保联合噻托溴铵对AECOPD患者PCT、TIMP－1、MMP－9、IFN－γ、动脉血气及肺功能水平的影响[J].海南医学院学报,2017,23(20):2761-2764.[12]李铁英.糖皮质激素对重度慢性阻塞性肺疾病急性加重期患者血清基质金属蛋白酶9和基质金属蛋白酶组织抑制因子1水平的影响研究[J].实用心脑肺血管病杂志,2016,24(2):28-31.[13]余霓雯,王玉婷.噻托溴铵联合布地奈德福莫特罗对慢性阻塞性肺疾病的疗效及血清TGF－β、MMP－9、TIMP－1水平的影响[J].东南国防医药,2017,19(2):183-186.[14]张知远,金海珍,余欣颐.慢阻肺急性加重期患者外周血T细胞中PD-1/PD-L1的表达及意义[J].中华全科医学,2020,18(3):419-422,426.[15]宋忠花.布地奈德福莫特罗吸入治疗对慢阻肺合并肺癌稳定期患者的疗效研究[J].河北医学,2018,24(8):1380-1384.[16]郁震,曹娟,王红梅,等.噻托溴铵联合沙美特罗替卡松对慢阻肺急性加重期患者免疫功能的影响[J].临床肺科杂志,2016,21(5):795-798.[17]郝文东,王国芳,张彩莲.百令胶囊联合布地奈德福莫特罗粉吸入剂治疗稳定期慢性阻塞性肺疾病的疗效及机制[J].临床肺科杂志,2016,21(9):1603-1606.[18]刘雪琴,关晓暄,孙立军.噻托溴铵联合沙美特罗/氟替卡松治疗哮喘-慢阻肺重叠综合征的临床评价[J].临床肺科杂志,2017,22(3):513.[19]崔鹏鹏.布地奈德福莫特罗吸入联合噻托溴铵对慢阻肺急性加重期患者呼吸力学及血气分析的影响[J].实用中西医结合,2021,21(5):12-13.

相似文献/References:

[1]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
　CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(23):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[2]张 斌,刘宿慧,余长寿.孟鲁司特联合噻托溴铵对COPD患者血清细胞因子、血液流变学及肺功能的影响[J].医学信息,2020,33(02):144.[doi:10.3969/j.issn.1006-1959.2020.02.043]
　ZHANG Bin,LIU Su-hui,YU Chang-shou.Effect of Montelukast Combined with Tiotropium Bromide on Serum Cytokines,Hemorheology and Lung Function in Patients with COPD[J].Medical Information,2020,33(23):144.[doi:10.3969/j.issn.1006-1959.2020.02.043]
[3]陈小军.布地奈德联合噻托溴铵治疗哮喘-慢阻肺重叠综合征的疗效[J].医学信息,2020,33(06):154.[doi:10.3969/j.issn.1006-1959.2020.06.051]
　CHEN Xiao-jun.Efficacy of Budesonide Combined with Tiotropium Bromide in the Treatment of Asthma-COPD Overlap Syndrome[J].Medical Information,2020,33(23):154.[doi:10.3969/j.issn.1006-1959.2020.06.051]
[4]孙 茜.布地奈德福莫特罗联合噻托溴铵吸入剂治疗慢性阻塞性肺疾病的疗效[J].医学信息,2022,35(20):60.[doi:10.3969/j.issn.1006-1959.2022.20.014]
　SUN Qian.Efficacy of Budesonide Formoterol Combined with Tiotropium Bromide Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease[J].Medical Information,2022,35(23):60.[doi:10.3969/j.issn.1006-1959.2022.20.014]
[5]曹进明.噻托溴铵与异丙托溴铵治疗慢阻肺的效果及对患者血清炎症因子的影响[J].医学信息,2022,35(21):131.[doi:10.3969/j.issn.1006-1959.2022.21.034]
　CAO Jin-ming.Effect of Tiotropium Bromide and Ipratropium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease and its Effect on Serum Inflammatory Factors[J].Medical Information,2022,35(23):131.[doi:10.3969/j.issn.1006-1959.2022.21.034]
[6]王丽丽,石景瑜,张 敏.布地奈德福莫特罗联合噻托溴铵治疗慢阻肺稳定期的临床疗效及药理学分析[J].医学信息,2022,35(23):136.[doi:10.3969/j.issn.1006-1959.2022.23.028]
　WANG Li-li,SHI Jing-yu,ZHANG Min.Clinical Efficacy and Pharmacological Analysis of Budesonide Formoterol Combined with Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Medical Information,2022,35(23):136.[doi:10.3969/j.issn.1006-1959.2022.23.028]
[7]王浩凌,李冬琼,吴 旭,等.布地奈德联合噻托溴铵治疗慢阻肺的效果及对CRP、SaO2、pH水平的影响[J].医学信息,2023,36(06):143.[doi:10.3969/j.issn.1006-1959.2023.06.031]
　WANG Hao-ling,LI Dong-qiong,WU Xu,et al.Effect of Budesonide Combined with Tiotropium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease and its Effect on CRP,SaO2 and pH Levels[J].Medical Information,2023,36(23):143.[doi:10.3969/j.issn.1006-1959.2023.06.031]
[8]孙 茜,柴明思,齐秀芳.布地奈德福莫特罗联合噻托溴铵吸入剂治疗慢阻肺的疗效及对CRP、SaO2、pH水平影响[J].医学信息,2023,36(10):150.[doi:10.3969/j.issn.1006-1959.2023.10.033]
　SUN Qian,CHAI Ming-si,QI Xiu-fang.Efficacy of Budesonide Formoterol Combined with Tiotropium Bromide Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease and its Effect on CRP, SaO2 and pH Levels[J].Medical Information,2023,36(23):150.[doi:10.3969/j.issn.1006-1959.2023.10.033]
[9]骈晓亮.吸入用激素联合噻托溴铵治疗慢性阻塞性肺疾病的临床疗效[J].医学信息,2022,35(05):105.[doi:10.3969/j.issn.1006-1959.2022.05.026]
　PIAN Xiao-liang.Clinical Effect of Inhaled Hormone Combined with Tiotropium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease[J].Medical Information,2022,35(23):105.[doi:10.3969/j.issn.1006-1959.2022.05.026]
[10]张志忠.布地奈德、左沙丁胺醇与噻托溴铵联合治疗对慢阻肺患者呼吸功能及机体炎性反应的影响[J].医学信息,2024,37(24):16.[doi:10.3969/j.issn.1006-1959.2024.24.005]
　ZHANG Zhizhong.Effect of Budesonide, Levosalbutamol Combined with Tiotropium Bromide on Respiratory Function and Inflammatory Response in Patients with Chronic Obstructive Pulmonary Disease[J].Medical Information,2024,37(23):16.[doi:10.3969/j.issn.1006-1959.2024.24.005]

更新日期/Last Update: 1900-01-01